AstraZeneca (AZN) CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on pharmaceuticals and said a more favorable corporate tax credit could motivate ...

AstraZeneca's Breztri met primary goals in four asthma trials, including KALOS, LOGOS, LITHOS, and VATHOS, involving over ...

Revenues came in at $13.59 billion, missing Wall Street's estimates of $13.76 billion. In this photo illustration, the AstraZeneca logo is displayed on a smartphone screen with a stock market chart in ...

April 16 (Reuters) - AstraZeneca's (AZN.L), opens new tab Alexion Pharmaceuticals was sued in Massachusetts federal court on Wednesday in a class action complaint alleging it misused its patents ...

BNP Paribas Exane initiated coverage of AstraZeneca (AZN) with an Outperform rating and $75 price target Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter ...

The CEO of FTSE 100 giant Astrazeneca has spoken out. (Photo by Christopher Furlong/Getty Images) Europe is putting its “ability to protect the health of its own people at risk” by not ...

AstraZeneca has announced positive high-level results from its Phase III KALOS and LOGOS trials, showing significant promise ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs. Tempus will use its “vast ...